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Many patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale
several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the
available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in
vitro studies and a thorough literature search.
Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients
contained in some of the tested drug products could be identiﬁed as a reason for incompatibilities, e.g. impaired activity of dornase alfa. Studies
assessing the aerosol characteristics of compatible mixtures nebulized with commonly used nebulizers are limited and should be encouraged. The
clinical efﬁcacy of simultaneous inhalation of duplicate, tripartite or quadripartite mixtures must be evaluated in clinical studies before ﬁnal
recommendations for the inhalation regimens can be made.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Nebulizer solution/suspension; Compatibility; Mixture; Aerosol; Review
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airway diseases widely rely on inhalation therapy. Besides dry
powder inhalers (DPI) and metered dose inhalers (MDI)
nebulizers are used, although nebulization is much more time
consuming than inhaling with a DPI or MDI. In contrast to
DPI's and MDI's, nebulizers deliver the drugs continuously
and larger doses can be administered. For children nebulization
is advantageous because the coordination requirements are
less strict [1]. They often cannot handle a MDI since the
coordination of medication release (i.e. actuation of the device)
and simultaneous inhalation is too difficult. Concerning DPI's,
children aren't able to generate the peak inspiratory flow (PIF)
necessary to release the drug [2].
Studies indicate that different nebulizer systems from different
manufacturers, i.e. ultrasonic, jet, or vibrating membrane
nebulizers with ventilator, humidifier or Y-piece, generate
different aerosol mass distribution profiles and thus, drug
deposition in the airways varies [3–8]. Adequate drug delivery
can be achieved if a specific medicinal product approved for
nebulization is prescribed together with a specific nebulizer which
was evaluated to be an effectively functioning drug-device
combination [5]. But apart from that, daily practice is even
worse, especially if patients have to inhale several drugs per dose
interval. Instead of cleaning, reassembling and refilling the
nebulizer to perform consecutive nebulization at least 25% of
patients save time by mixing the inhalation solutions/suspensions
[9,10]. Nebulization of medication mixtures increases the aerosol
output of the nebulizer while its dead volume remains the same. If
nebulization is continued until the nebulizer runs dry, total mass
output and inhaled mass of the nebulized drug will rise [11–14].
However, incompatibility and/or instability of the medication
mixtures can lead to impaired drug safety and/or reduced efficacy
up to treatment failure.
Further, simultaneous nebulization of inhalation solutions can
affect drug delivery by altering the aerosol particle size distribution.
Particle size should be 1 to 5 μm in diameter, because larger
particles will deposit in the upper airways and smaller particles
may be exhaled [15]. Hence, even if physico-chemical compati-
bility of mixtures is proven final recommendations for simulta-
neous inhalation cannot be made. Aerodynamic characteristics ofmixtures need to be studied. In addition, the clinical relevance of
inhaling different drugs simultaneously and the differences in
therapeutic outcome compared to consecutive inhalation should be
investigated.
Drug substances commonly prescribed for nebulization
therapy in Europe comprise the bronchodilators albuterol
(salbutamol) and ipratropium bromide, the corticosteroids
budesonide and fluticasone-17-propionate, the antibiotics
tobramycin and colistimethate, and dornase alfa. In addition,
formoterol, acetylcysteine, sodium chloride solutions (0.9% to
7%), and the mast cell stabilizer cromolyn are used.
In 2006 we published our first results concerning physico-
chemical compatibility and stability of several nebulizable drug
solutions/suspensions predominantly used in Europe [10]. Since
then various mixtures have been experimentally tested by us and
other groups, also in regard to the resulting aerosol characteristics.
Results were published in several articles of the primary literature
and Burchett et al. developed a preliminary compatibility guide for
aerosolized medications used in the US [16]. In this issue we
present a comprehensive overview of the available data based on
our own studies and the search of relevant literature as well as the
up-to-date version of the compatibility data in table format.
2. Methods
2.1. Physico-chemical compatibility of nebulizable drug mixtures
In the following paragraphs we present an overview of the
methods used to determine the physico-chemical compatibility
of duplicate, tripartite and quadripartite drug solutions/suspen-
sions inhaled via nebulizers. According to the conventional
definition of compatibility, mixtures of inhalation medications
can be designated as physico-chemical compatible, when
chemical stability (≤10% degradation) of each active substance
and unchanged pH values, osmolality and physical appearance
are given over a test period of ≤24 h. In general, potencies or
concentrations of the active substances of the mixtures were
determined under specified conditions.
2.1.1. Preparation of admixtures
Test solutions/suspensions were prepared by mixing com-
monly used doses of medication approved and marketed in
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refrigeration and exposed to light for several hours. Analyses
were performed immediately after preparation and after defined
intervals [17–20].
2.1.2. Physical compatibility
Physical compatibility of the inhalation mixtures was
determined by visual inspection for any changes up to 24 h
after mixing as well as by measuring pH and osmolality
[17–21]. Mixtures were designated as physically incompatible
when color or odor changed, and haze or precipitation occurred.
The lack of physical incompatibility does not rule out chemical
decomposition.
2.1.3. Chemical compatibility (Table 1)
Potencies of antibiotics in inhalation mixtures were determined
by fluorescence immunoassay (tobramycin) [18,21] or by using
the ‘Microbiological assay of antibiotics’ (agar diffusion assay) of
the European Pharmacopoeia (Ph. Eur.) in comparison to a
reference standard (colistimethate, tobramycin) [17,22].
Dornase alfa activity was determined by a kinetic colorimetric
DNase activity assay [18,20]. Stability of dornase alfa was
determined by size-exclusion high performance liquid chroma-
tography (SE-HPLC), ultraviolet spectroscopy, sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
tentacle strong cation-exchange chromatography [21].
Concentrations of the corticosteroids (budesonide and
fluticasone-17-propionate) and the bronchodilators (ipratropium
bromide and albuterol) were measured by stability-indicating high
performance liquid chromatography assays with ultraviolet
detection (RP-HPLC) [17,19,20,22,23].
2.2. Aerosol characteristics
A subset of mixtures was analyzed in regard to their aerosol
characteristics after nebulization with the PARI eFlow® rapid.
Particle size distribution, Mass Median Aerodynamic Diameter
(MMAD), Geometric Standard Deviation (GSD) and Fine ParticleTable 1
Analytical methods (own data only) used to determine chemical compatibility
of mixed nebulizer solutions/suspensions.
Drug Method
Dornase alfa Kinetic colorimetric DNase activity assay
Size-exclusion high performance liquid chroma-
tography (SE-HPLC)
Ultraviolet spectroscopy
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE)
Tentacle strong cation-exchange chromatography
Tobramycin Fluorescence immunoassay, microbiological assay
of antibiotics Ph. Eur.
Colistimethate Microbiological assay of antibiotics
(agar diffusion assay) Ph. Eur.
Budesonide RP-HPLC: stability-indicating high performance
liquid chromatography with ultraviolet detection
Fluticasone-17-propionate RP-HPLC
Ipratropium bromide RP-HPLC
Albuterol RP-HPLCFraction (FPF; particles b5 μm) were determined via cascade
impaction with the Next Generation Pharmaceutical Impactor
(NGI) in comparison to aerodynamic parameters of unmixed
solutions under specified conditions (Fig. 1). RP-HPLC and
SE-HPLC were used to assess drug concentrations deposited on
each impactor stage, in the induction port and in the nebulizer. We
tested duplicate mixtures of dornase alfa and tobramycin, i.e.
Pulmozyme® with Bramitob® and Pulmozyme® with TOBI®
(Table 3) as well as the tripartite mixture of ipratropium bromide,
albuterol and fluticasone-17-propionate, i.e. Atrovent®, Sultanol®
forte and Flutide® forte.
2.3. Literature search
In order to get additional information about the compatibility/
stability of mixed nebulizer solutions/suspensions for inhalation
therapy we searched the literature databases “Medline” and
“International Pharmaceutical Abstracts” for combinations of
the terms “nebulizer solution”, “inhalation”, “aerosol”, “compat-
ibility”, “stability”, “combination”, “HPLC”, and “aerodynamic
behavior”.
3. Results and discussion
Both, the results of our own experimental studies and of the
literature search are presented together for the respective
nebulizable drug mixtures. (In)compatibility results for the
eight most commonly used drugs in inhalation therapy are
finally summarized in table format (Table 4). Further we
introduce particular tripartite and quadripartite mixtures ana-
lyzed for physico-chemical compatibility and discuss the
impact of certain excipients commonly used to formulate
nebulizer solutions, i.e. preservatives and stabilizers. Finally,
we present results from our aerodynamic studies performed
with cascade impaction.
3.1. Dornase alfa
Dornase alfa (Pulmozyme®) is a mucolytic drug substance
that decreases viscoelasticity and adherence of sputum,
improves lung function and reduces respiratory exacerbations
in cystic fibrosis (CF) patients. Administration is usually
carried out via jet nebulizers, but a recent study indicates that
perforated vibrating membrane devices deliver the drug more
efficiently [3].
CF patients often mix dornase alfa with bronchodilatators like
ipratropium bromide (Atrovent® and Atrovent® Fertiginhalat) and
albuterol (Sultanol® and Sultanol® forte Fertiginhalat). Our studiesFig. 1. Schematic test set-up of the impaction experiments.
Table 2
Results of the HPLC assays of quadripartite mixtures containing Colistin CF,
Atrovent, Sultanol forte and Flutide forte [17].
n = 9 Ipratropium
bromide
Salbutamol
sulfate
Fluticasone-17-
propionate
Nominal concentration [μg/ml] 55.55 26.66 22.22
Arithmetic mean ± relative
SD [μg/ml]
58.4 ± 0.55 27.68 ± 0.35 23.82 ± 0.32
Percentage rate of nominal
concentration
105.13 103.80 107.20
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chloride, used as excipient in Atrovent® and Sultanol®, and
disodium edetate used as an excipient in Atrovent®. But in the
mixtures of Pulmozyme® with the preservative-free single dosage
forms of Atrovent® 500 mg/2 mL Fertiginhalat or Sultanol® forte
2.5 mg/2.5 mL Fertiginhalat a decrease of dornase alfa activity
was hardly measurable. Thus, these mixtures are most probably
compatible [20]. To ensure this designation a more precise assay
for determination of dornase alfa activity has to be applied and the
nebulization properties of the proposed inhalation mixture have to
be studied. Correspondent experimental studies were later on
performed for mixtures of dornase alfa and tobramycin (see
following paragraph). Ipratropium bromide and albuterol concen-
trations were not affected by mixing the drug products [20].
Concomitant inhalation of dornase alfa and antibiotics seems to
be advantageous for antipseudomonal treatment [24] and thus, in
daily practice many CF patients mix the drug with antibiotics,
mainly tobramycin, which is available on the market in different
formulations manufactured by different pharmaceutical compa-
nies. We analyzed activity and stability of dornase alfa after it was
mixed with Tobi®, Bramitob® or Gernebcin®. We found no
physical incompatibilities or decomposition in mixtures with
Tobi® and Bramitob® [21], whereas the mixture with Gernebcin®
is designated as incompatible. Results indicated that dornase alfa
activity was especially affected by sodiummetabisulfite used as an
excipient in Gernebcin® (not in Tobi® and Bramitob®), since the
activity loss was most pronounced when Pulmozyme®was mixed
with pure solutions of sodium metabisulfite [18]. Tobramycin
concentrations were not affected in any of the mixtures.
Mixed inhalation solutions of dornase alfa and the corticoste-
roid fluticasone-17-propionate (Flutide® forte Fertiginhalat) are
considered as incompatible. Enzymatic activity of dornase alfa
measured at room temperature declined from initially 93% ofTable 3
Nebulizer and aerosol characteristics of Pulmozyme® mixed with 0.9% NaCl
solution, Bramitob® or Tobi®. Results expressed as mean ± SD of triplicate
assays of 4 test solutions [21].
Pulmozyme® mixture with
n = 12 0.9% NaCl solution Bramitob® TOBI®
Nebulization time
[min] ± SD
5.85 ± 0.10 5.46 ± 0.22 5.66 ± 0.33
Delivered dose [%] ± SD 73.91 ± 2.78 74.41 ± 3.97 76.56 ± 2.62
MMAD [μm] ± SD 4.75 ± 0.13 4.73 ± 0.17 4.70 ± 0.08
GSD ± SD 1.65 ± 0.06 1.60 ± 0.00 1.63 ± 0.05
FPF b 5 μm [%] ± SD 54.36 ± 2.5 55.14 ± 2.5 54.70 ± 1.72nominal activity to 72% after 24 h, probably due to the phosphate
buffer used in Flutide® forte. Dornase alfa activity was hardly
impaired in mixtures with the corticosteroid budesonide
(Pulmicort®). Enzymatic activities measured up to a 31 hour
interval after mixing resulted in at least 86% of the nominal
activity and the mixtures were designated as compatible [25].3.2. Antibiotics
3.2.1. Tobramycin
We investigated the compatibility of tobramycin and
colistimethate nebulizable drug admixtures although we are
aware that at present simultaneous inhalation is not an accepted
standard in cystic fibrosis patients. However, mixing both
antibiotics is practiced by patients, especially for treatment of
mucoid Pseudomonas aeruginosa infections [26]. If antibiotic
combination therapy via inhalation becomes clinically relevant, the
physico-chemical compatibility of tobramycin and colistimethate
is one of the prerequisites for simultaneous inhalation. Our study
revealed that neither colistimethate nor tobramycin showed any
losses of antibiotic potency after mixing. Values of pH and
osmolality remained unchanged [27].
Physico-chemical compatibility of tobramycin (Nebcin®,
40 mg/mL) and albuterol (Ventolin®) has been proven earlier
[28]. Our compatibility studies concerningmixtures of tobramycin
(Tobi® and Gernebcin®) with the corticosteroids fluticasone-
17-propionate (Flutide® forte Fertiginhalat) or budesonide
(Pulmicort®) revealed that eight hours after mixing tobramycin
concentrations remained unchanged, i.e. at a minimum of 96% of
the nominal concentration [25].3.2.2. Colistimethate
Pulmonary infections with Gram-negative bacteria resistant to
tobramycin or other antibiotics in CF patients may require the
inhalation of colistimethate in addition to standard inhalation
therapy. Thus, we tested the physico-chemical compatibility of a
quadripartite mixture containing colistimethate (Colistin CF) and
the anticholinergic ipratropium bromide (preservative-free dosage
form of Atrovent®), the β2-agonist albuterol (preservative-
free dosage form of Sultanol® forte), and the corticosteroid
fluticasone-17-propionate (preservative-free Flutide® forte).
Based on the results (see Section 3.9) we assume that incom-
patibilities in duplicate and triplicate mixtures containing
colistimethate and one or two of the tested substances are unlikely.
But results apply only to the preservative-free single dose
formulations of these drugs [17].
Compatibility of colistimethate (Colistin® CF) and the
glucocorticoid budesonide (Pulmicort®) was also tested. The
duplicate mixture showed no loss in drug concentration of
budesonide and no change in antibiotic activity of colistimethate
over a period of 24 h after mixing. During the first six hours after
mixing an increase of the pH (5.5 to 7.3) was measured [22] and
according to the definition of compatibility the mixture is to be
categorized as incompatible. But because no other parameters, i.e.
osmolality and physical appearance, were altered and chemical
stability of the active substances was given over a period of 24 h,
Table 4
Physico-chemical compatibility of inhalation solutions/suspensions. No sufficient information available for yellowmarked combinations. *Mixtures not recommendable from
a clinical viewpoint. **Compatibility applies only to preservative-free dosage forms. #Unchanged aerosol characteristics and drug output have been proved.
Mixable# Do not mix Do not mix Do not mix Do not mix Mixable Do not mix Do not mix Do not mix
Mixable# Mixable Mixable Mixable Mixable Mixable Do not mix Do not mix
Do not mix Mixable Mixable Mixable Mixable Mixable Do not mix Do not mix
Do not mix Mixable Mixable Mixable** Mixable** Mixable Mixable Do not mix Mixable
Do not mix Mixable Mixable Mixable** Mixable# Mixable Mixable# Mixable** Do not mix
Do not mix Mixable Mixable Mixable** Mixable# Mixable Mixable# Mixable** Do not mix
Mixable Mixable Mixable Mixable Mixable Mixable * Mixable Mixable
Do not mix Mixable Mixable Mixable Mixable# Mixable# * Do not mix Do not mix
Do not mix Do not mix Do not mix Do not mix Mixable** Mixable** Mixable Do not mix Do not mix
Do not mix Do not mix Do not mix Mixable Do not mix Do not mix Mixable Do not mix Do not mix
Dornasealfa Tobramycin Tobramycin Colistimethate Ipratropium Albuterol Budesonide Fluticasone–
17–propionate
Cromolyn Hypertonic
salinePulmozyme® Bramitob®
TOBI®
Gernebcin® Colistin CF® Atrovent®,
Atrovent®unit 
dose 2 ml
Sultanol®,
Sultanol®unit 
dose 2.5 ml
Pulmicort®
Flutide®
Intal®
5.85% NaCl
solution
Dornasealfa
Tobramycin
Bramitob®,TOBI®
Tobramycin
Gernebcin®
Colistimethate
Ipratropium
Albuterol
Budesonide
Fluticasone–17–
propionate
Cromolyn
Hypertonic
saline
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physico-chemically compatible [22].
We also studied compatibility of admixtures containing
colistimethate and 5.85% sodium chloride solution, since
nebulized hypertonic saline solution has been established as an
effective adjunctive therapy for respiratory symptoms in CF
patients [29,30]. We found the mixture to be physico-chemically
compatible and stable over a period of 48 h stored under
refrigeration [17].
3.3. Ipratropium bromide
We evaluated the physico-chemical compatibility of the
anticholinergic ipratropium bromide (Atrovent® LS), the β2-
agonist albuterol (Sultanol®) and the corticosteroid fluticasone-
17-propionate (Flutide® forte) by experimental studies of the
tripartite mixture with validated analytical assays (see Section
3.9). We found compatibility over a period of five hours, i.e.
almost no changes in drug concentrations, pH and osmolality
could be detected and no visible changes occurred [19]. Thus, we
consider the duplicate mixtures of these drug products to be
compatible.
Compatibility of different formulations of ipratropium
bromide (Atrovent®, Duovent®, i.e. fenoterol plus ipratropium)
and budesonide (Pulmicort®) were tested by different working
groups. No evidence of any physico-chemical incompatibility
was found [10,31,32].
When ipratropium bromide and cromolyn (Intal®) contain-
ing inhalation solutions were mixed compatibility was given
only with the preservative-free formulation of Atrovent®
[10,33–35].Finally, a study from China raised concerns about the
packaging material of ipratropium bromide containing aerosol
products. Yue et al. [36] reported that the active substance is
absorbed and leachable additives from the primary package
may be present in the drug solution.3.4. Albuterol and levalbuterol
In Europe the most common β2-agonist prescribed is
albuterol, but its stereoisomer levalbuterol is widely used in
the US. Both substances have similar pharmacokinetic and
pharmacodynamic properties. We concentrated on albuterol
whereas in one recently published study the compatibility
of different duplicate mixtures containing levalbuterol was
evaluated.3.4.1. Albuterol
In several studies the compatibility and stability of mixtures
of albuterol and ipratropium bromide was proven [19,35,37].
Moreover, there are combination products for nebulization
available which contain both albuterol and ipratropium bro-
mide, e.g. Berodual® LS in Germany and DuoNeb® in the US.
For these products stability is proven.
Several studies proved the compatibility of albuterol
(Proventil® or Xopenex®) and budesonide (Pulmicort®) [10].
Recently Melani [38] tested the aerosol characteristics of this
particular drug mixture (see Section 3.11.).
The mixture of albuterol (Ventolin®) and cromolyn (Intal®)
was also found to be compatible [10,39].
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Bonasia et al. [40] investigated several two-drug admixtures
of levalbuterol by visual inspection, pH measurement and high
performance liquid chromatography (HPLC assays). For
duplicate nebulizable drug admixtures containing levalbuterol
and budenoside, ipratropium bromide, cromolyn (DNCG), or
acetylcysteine sodium no evidence of physical incompatibility
and/or chemical decomposition were registered over a period of
at least 30 minute storage at room temperature.
Yamreudeewong et al. evaluated the stability of a mixture
containing levalbuterol and ipratropium over a period of 28 days
at room temperature. They found no significant decrease in
concentrations of the active drugs, i.e. decrease in concentration of
each drug was below 10% of the initial concentration [41].
3.5. Budesonide
Compatibility of budesonide and cromolyn is known [10,
31,42]. When budesonide nebulizable suspension (Pulmicort®)
was mixed with 5.85% sodium chloride solution no loss in drug
concentration of budesonide was detected over a test period of
24 h. Osmolality and pH remained unchanged and visual
inspection revealed no abnormality [22].
3.6. Cromolyn
Although cromolyn is not a standard therapy in cystic fibrosis
we decided to report compatibility with other nebulizable drug
products. As stated before [10], 7% of patients at our CF center
reported inhaling cromolyn mixed with other drugs and
prescribing information about miscibility with cromolyn is not
consistent. Information about compatibility is reported in the
above Sections 3.3, 3.4.1, and 3.5.
3.7. Hypertonic sodium chloride solution
We determined the physico-chemical compatibility of 5.85%
sodium chloride (NaCl) solution with either colistimethate (see
Section 3.2.2) or budesonide (see Section 3.5). Fox et al. [43]
assessed the physical compatibility of eleven nebulizable drug
products with 7% sodium chloride solution. The duplicate
mixtures of 7% NaCl solution and acetylcysteine, albuterol,
atropine, cromolyn sodium, dexamethasone, glycopyrrolate,
ipratropium, metaproterenol, sodium bicarbonate, terbutaline, or
tobramycin were analyzed by serial turbidimetric testing and
visual inspection. The authors stated compatibility for all different
mixtures, except for cromolyn sodium, which was found to be
visually incompatible with 7% NaCl solution.
3.8. Miscellaneous
Formoterol and arformoterol were analyzed by Akapo et al.
[11] with regard to physico-chemical compatibility and aerody-
namic characteristics (see Section 3.11) of different duplicate
mixtures. They found compatibility for formoterolfumarate
20 mg/2 ml when mixed or sequentially nebulized with bu-
desonide inhalation suspension 0.5 mg/2 ml, ipratropiumbromide 0.5 mg/2.5 ml, cromolyn sodium 20 mg/2 ml, or 10%
acetylcysteine solution (100 mg/ml). However, mixing or se-
quential nebulization significantly increased the amount of drug
delivered compared with single drug nebulization and the authors
emphasize that clinical implications of the in vitro data have not
been determined.
The chemical and physical compatibility of duplicate mix-
tures of arformoterol (15 mg/2 ml) with ipratropium bromide
(0.5 mg/2.5 ml), acetylcysteine (800 mg/4 ml), or budesonide
(0.25 mg/2 ml and 0.5 mg/2 ml) was tested. Visual inspection,
pH measurement, and HPLC assays of each active component
revealed no signs of incompatibility in any of these mixtures [44].
3.9. Tripartite and quadripartite mixtures
We analyzed several tripartite mixtures containing the anti-
cholinergic ipratropium bromide (Atrovent® LS) and the β2-
agonist albuterol (Sultanol®). Physico-chemical compatibility was
proven with fluticasone-17-propionate (Flutide® forte) [19].
Mixtures of albuterol, tobramycin and ipratropium bromide (no
information available about studied brands) were found to be
compatible, too [10].
In mixtures with cromolyn (Intal®) compatibility is given for
mixtures prepared with the preservative-free single use dosage
forms Atrovent® Fertiginhalat and Sultanol® forte Fertiginhalat
[34]. Compatibility seemed to be affected by certain excipients
like benzalkonium chloride. In order to minimize the risk of
physical incompatibility, only preservative-free formulations of
albuterol or ipratropium bromide inhalation solutions should be
mixed with Intal® [10,34].
Comparable results were obtained after mixing ipratropium
bromide and albuterol with dornase alfa (Pulmozyme®).
Dornase alfa activity was more compromised in mixtures
containing the excipients benzalkonium chloride and disodium
edetate. Thus, the preservative-free single use dosage forms
Atrovent® Fertiginhalat and Sultanol® forte Fertiginhalat are
designated as mixable with Pulmozyme® without reducing the
efficacy of dornase alfa [20].
The compatibility of Berodual® and Pulmicort® was tested in
an experimental setting. The tripartite mixture, i.e. Berodual®
which contains ipratropium bromide and fenoterol, turned out to
be physico-chemically compatible [10,34].
We analyzed the physico-chemical compatibility of
colistimethate (Colistin CF), fluticasone-17-propionate (Flutide®
forte), ipratropium bromide and albuterol. This quadripartite
mixture was found to be compatible, but only when preservative-
free single-dose formulations of the drug products (Atrovent®
Fertiginhalat, Sultanol® forte Fertiginhalat) were used (Table 2).
3.10. Excipients
Many multiple dosage forms of inhalative drugs contain not
only the active agent but also excipients as preservatives and
stabilizers, e.g. benzalkonium chloride, disodium edetate, and
sodium metabisulfite. Our studies revealed that most probably
these additives are responsible for detected incompatibilities, e.g.
limited activity of dornase alfa (Pulmozyme®) and colistimethate
249W. Kamin et al. / Journal of Cystic Fibrosis 13 (2014) 243–250(Colistin® CF). Hence, patients should be informed about
possible incompatibilities caused by excipients and should be
educated to check the excipients declared on the package and
package insert of each medicinal product.
3.11. Aerosol characteristics
Aerosol output of the nebulizer and particle size distribution of
the aerosol produced are the most important issues for successful
inhalation therapy, since particle size influences the deposition
pattern and bioavailability of drugs delivered to the respiratory
system [45]. Special conditions are required for an effective
inhalation therapy of infants and young children [46]. To figure out
if mixing of dornase alfa (Pulmozyme®) and tobramycin (Tobi®
and Bramitob®) causes changes in particle size distribution, the
physico-chemical compatible admixtures (see Section 3.1) were
nebulized with the PARI eFlow® rapid. Aerosol characteristics, i.e.
MMAD, GSD and FPF, of dornase alfa were assessed via cascade
impaction with the NGI. SE-HPLC was used to assess the dornase
alfa concentrations deposited on the impactor stages. The aerosol
patterns of admixtures of dornase alfa and tobramycin were
compared to those of dornase alfa diluted with 0.9% sodium
chloride solution in order to achieve the same volume. There was
no difference in particle size distribution, MMAD, GSD and FPF
(Table 3).
Melani [38] evaluated the aerosol output, drug output, and
aerosol particle size characteristics of two corticosteroids
(budesonide, beclomethasone dipropionate) and two broncho-
dilators (albuterol, ipratropium bromide) when nebulized alone
or in tripartite mixtures (budesonide or beclomethasone and
albuterol and ipratropium).
Using the SideStream and VentStream-Pro nebulizers, run
with the AirClinic compressor, the author found that mixing
reduced drug output and increased mass median aerodynamic
diameter (MMAD) with the SideStream, but not always with
the VentStream-Pro. However, drug output and MMAD never
reached critical values, i.e. outside the respirable range. When
nebulized alone, the respirable mass of bronchodilators ranged
from 18% to 40% of the nominal dose compared to 13% to
37% when mixed. The respirable mass of corticosteroids
nebulized alone ranged from 10% to 24% of the nominal dose,
in mixtures it ranged from 10% to 17%. Hence, both nebulizers
can be recommended in terms of aerosol performance for
inhalation therapy with these particular drug mixtures.
Akapo et al. [11] assessed the aerodynamic characteristics of
formoterol fumarate (20 mg/2 ml) when mixed or sequentially
nebulized with budesonide inhalation suspension (0.5 mg/2 ml),
ipratropium bromide (0.5 mg/2.5 ml), cromolyn sodium
(20 mg/2 ml), or acetylcysteine 10% (100 mg/ml). Aerosols
were generated with a Pari LC Plus® nebulizer and characterized
by using an 8-stage cascade impactor. They found a significantly
increased respirable fraction/delivered dose (p b 0.05) for the
mixed or sequentially nebulized drugs and assume that this was
due to an increased drug volume or reconcentration in the
nebulizer cup by sequential nebulization. Both facts decreased
the amount of drugs retained in the dead volume. In contrast, the
FPF, MMAD, and GSD generally remained unchanged for alladmixtures, except for the FPF of the formoterol/budesonide
combination. This may be caused by polysorbate 80 used as
surfactant in the budesonide formulation. The authors conclude
that mixing or sequential nebulization significantly increases the
amount of drug delivered compared with single drug nebulization.
Itazawa et al. [47] analyzed the aerosol characteristics of a
duplicate mixture containing budesonide (Pulmicort®) and the
β2-agonist procaterol (Meptin®). They found no relevant differ-
ences in drug output and particle size distribution with regard to
budesonide when nebulized alone or in the admixture. In contrast,
they detected a significantly higher amount of delivered procaterol
and a higher rate of smaller particle sizes containing procaterol in
the admixture compared to the unmixed solution.
The physico-chemical compatible tripartite mixture containing
fluticasone-17-propionate (Flutide® forte), albuterol (Sultanol®
forte Fertiginhalat) and ipratropium bromide (Atrovent®
Fertiginhalat) [19] was nebulized by Stanko and the aerosol
characteristics were analyzed. Particle size distribution, MMAD,
GSD, and FPF were assessed via cascade impaction and results
revealed no relevant changes [34].4. Conclusion
Our in vitro studies and search of relevant literature indicate
that most of the tested nebulizer suspensions are mixable without
provoking any measurable incompatibilities. A major exception is
dornase alfa. Its activity was affected by certain excipients
contained in some of the drug products. The same excipients
caused incompatibility when albuterol and/or ipratropium bro-
mide was mixed with cromolyn or colistimethate.
Mixtures should always be prepared directly before inhalation
and surplus quantities should be discarded.
Only a limited number of mixtures have been tested yet with
regard to aerosol characteristics. More studies assessing particle
size distribution of common mixtures administered with popular
nebulizers are needed.
Finally, the clinical efficacy of inhalation therapy with
duplicate, tripartite or even quadripartite mixtures must be
evaluated in comparison to consecutive inhalation of the same
drugs, before final recommendations for patients can be made.Acknowledgments
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